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Abstract
Although congenital cytomegalovirus (cCMV) is the leading non-genetic cause of childhood hearing loss in the United 
States, neither targeted nor universal screening protocols have been well established to identify cCMV in newborns. 
Moreover, until cCMV testing is universal, clinical protocols need to account for the complexities of individualized care in 
partnership with interprofessional care teams. This work addressed an immediate clinical practice need to identify cCMV 
with subsequent hearing monitoring of babies who test positive for cCMV. This effort focused on three primary objectives 
to: (a) define interprofessional, team-based approach to facilitate care pathways; (b) develop a clinical workflow for all 
babies who refer on inpatient hearing screening to be tested for cCMV by 21 days of age; and (c) develop a hearing 
monitoring plan for all babies who test positive for cCMV. The article describes the development and integration of our 
interprofessional, team-based approach to institute cCMV testing by 21 days of age on all babies who refer. Description 
of the inpatient newborn hearing screening and subsequent monitoring is also included. Our observed referral rate was 
lower than predicted (2.7%) from existing literature with only one positive cCMV outcome noted in the two-year span. This 
study demonstrates the feasibility of a hearing-targeted cCMV testing paradigm in our clinic practice.
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cytomegalovirus; DPOAEs = distortion product otoacoustic emissions; EHDI = Early Hearing Detection and Intervention; 
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Babies born with congenital cytomegalovirus (cCMV) 
infection may present with immediate and long-term health 
problems, one of which is hearing loss detectable at birth 
or developing later in childhood (reviewed by Goderis et 
al., 2014 and WHO, 2021). cCMV is common in the United 
States presenting in 1 out of 200 babies (~0.6%; Centers 
for Disease Control and Prevention [CDC], 2020; Fowler 
et al., 2018). Of babies infected with cCMV, about 10% are 
symptomatic at birth, 10 to 15% are asymptomatic at birth 
yet develop hearing loss or other neurological impairments 
at a later onset, and the remaining majority (75–80%) are 
asymptomatic (Boppana et al., 2013; CDC, 2020; Goderis 
et al., 2014; Kenneson & Cannon, 2007). Symptomatic 
babies may exhibit multiple system conditions because 
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of cCMV which may include thrombocytopenia, 
hyperbilirubinemia, or central nervous system involvement 
such as microcephaly with significant neonatal morbidity 
and mortality (e.g., Rawlinson et al., 2017).
Sensorineural hearing loss is the most common diagnosis 
for a baby infected with cCMV, whether symptomatic or 
asymptomatic for other systems’ involvement (Naing et 
al., 2016). Estimates suggest that cCMV accounts for 25 
to 40% of total hearing loss in children (Goderis et al., 
2014). Sensorineural hearing loss occurs in approximately 
20 to 40% of babies with multisystem involvement and 
is a single system finding in 5 to 10% of cCMV cases 
(Dollard et al., 2007; Fowler & Boppana, 2006, 2018; 
Goderis et al., 2014; Rawlinson et al., 2017). Although this 
is counter-intuitive, hearing loss has not been included 
in the definition of symptomatic cCMV; asymptomatic 
cCMV is a distinct category and can include hearing loss 
(Petersen et al., 2020; Rawlinson et al., 2017). Therefore, 
asymptomatic cCMV cases may present with hearing loss 
as the only clinical finding (Fowler & Boppana, 2006, 2018; 
Goderis et al., 2014).
Universal newborn hearing screening successfully detects 
congenital hearing impairment at birth; however, concerns 
for delayed onset or progressive hearing loss require longer 
term monitoring (Joint Committee on Infant Hearing [JCIH], 
2019; World Health Organization [WHO], 2021). At this time, 
screening for cCMV is not performed for all newborns. The 
debate over universal newborn cCMV screening versus 
targeted screening is ongoing. However, growing evidence 
and clinical practice goals of universal or extended neonatal 
cCMV screening aimed at detection of cCMV at the earliest 
are progressing (e.g., Krishna et al., 2020). Hearing-
targeted screening for cCMV can be one step in advancing 
toward the goal of universal cCMV testing for all newborns 
and for promoting earlier detection of delayed onset or 
progressive hearing loss (e.g., JCIH, 2019). That said, 
such targeted approaches are imperfect as they are biased 
toward missing cCMV positive cases with passed newborn 
hearing screening results (see review of considerations by 
Haller et al., 2020 and Krishna et al., 2020). Evidence in the 
realm of early detection has resulted in recommendations 
for inclusion of cCMV testing if sensorineural hearing loss 
is detected as a result of newborn hearing screening (Choi 
et al., 2009; Haller et al., 2020; Korver et al., 2017; Park 
& Shoup, 2018). Hearing-targeted cCMV screening and 
outcomes data (Diener et al., 2017; Fowler et al., 2017) 
support legislative efforts to mandate cCMV testing based 
on newborn hearing screening outcomes and potentially 
beyond (National CMV Foundation, 2021). Moreover, 
accounting for delayed-onset or progressive hearing loss 
over the first years of life is of growing importance (e.g., 
Cannon et al., 2014; WHO, 2021).
Early cCMV testing is critical as this is the only means to 
differentiate between congenital and postnatally acquired 
infection. Detection of cCMV can be made within the 
first weeks of life by detecting the virus from a culture or 
polymerase chain reaction (PCR) of body fluids such as 
urine or saliva (Boppanna et al., 2011; CDC, 2020). This 
is most helpful for timely detection of asymptomatic cCMV 
cases as positive cCMV tests within the first 14 to 21 days 
of life help distinguish congenital from acquired CMV 
(Revello & Gerna, 2002). Testing of the newborn screening 
card dried blood spots may permit later diagnosis of 
cCMV as such samples are collected in the desired 
timeframe and may retrospectively help to distinguish 
between congenital and acquired CMV (e.g., Choi et 
al., 2009). Only congenital CMV causes hearing loss 
or symptomatic disease; whereas, postnatally acquired 
infections are not associated with disease (e.g., Boppana 
et al., 2010; Choi et al., 2009; Meyer et al., 2017). In 
the case of cCMV, newborns who are symptomatic or 
asymptomatic will continue to shed and transmit the 
virus through bodily fluids for 18 to 30 months (Pati et al., 
2016). This knowledge is critical for treatment planning 
and consideration for antiviral therapy (Rawlinson et 
al., 2017). Timely diagnosis leads to timely intervention; 
specifically, all treatments began before 30 days of life in 
initial trials validated antiviral medications (Kimberlin et al., 
2003, 2015; Rawlinson et al., 2017). Similarly, continued 
monitoring for later onset of hearing loss in children who 
were positive for cCMV can help with earlier diagnosis of 
hearing loss, facilitate fitting of assistive hearing devices, 
and support earlier access to speech and language 
interventions (Boppana & Fowler, 2017; JCIH, 2019; 
Kennedy et al., 2006).
The work presented here developed from the immediate 
clinical practice need for Mayo Clinic Rochester and 
Mayo Clinic Health System (outreach clinical sites 
throughout Minnesota and Wisconsin) to converge 
on clinical practice approaches to identify cCMV and 
subsequently monitor babies who tested positive for 
cCMV in the newborn population. This effort focused on 
three primary study objectives that we developed (based 
on baseline program review from 2015–2017), deployed 
(January 2018), and reviewed over a two-year span 
(2018–2019). This article describes the development and 
integration of our interprofessional, team-based approach 
to quality improvement efforts to conduct cCMV testing 
by 21 days of age on all babies who refer (in at least 
one ear) on inpatient newborn hearing screening. It also 
describes the follow up process developed for ongoing 
hearing monitoring of this population. Specific project 
objectives include: (a) define interprofessional, team-
based approach to facilitate care pathways; (b) develop a 
quality improvement strategy where all babies who refer 
on inpatient hearing screening get cCMV testing by 21 
days of age; and (c) develop a hearing monitoring plan for 
all babies who test positive for cCMV, keeping in mind that 
some may be found to have normal hearing.
Method
Participants
All newborns at Mayo Clinic undergo newborn hearing 
screening according to Minnesota state guidelines 
(Minnesota Department of Health [MDH], 2021). The 
population at Mayo Clinic includes newborns who stay on 
a postpartum/newborn nursery unit (well child) with their 
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mothers and patients who stay on a Level III neonatal 
intensive care unit (NICU) and a Level IV NICU. Mayo 
Clinic Rochester has been conducting inpatient hearing 
screening on all newborns since 1999. The practice 
screens approximately 2335 newborns per year (5-year 
average) on the newborn nursery unit and two NICUs. 
Overview of the birth cohort focus for this evaluation pre- 
and post-screening for cCMV is detailed in Table 1.
Timing
Newborns on the nursery unit are typically seen for hearing 
screening on the first full day of life. Screening is typically 
completed late morning or early afternoon on the first 
day, so the patients may be in the range of 12 to 36 hours 
old when screening is completed. In either of the NICU 
settings, screening is conducted as the patient is getting 
closer to dismissal (typically within 1–2 weeks of dismissal).
Equipment
Screening is conducted using the Otodynamics Otoport 
TE+DP OAE+AABR equipment in all units. This is a 
handheld piece of equipment that plugs in to a computer 
kept on a cart and is transported to the newborn’s location 
for screening. This allows the screener to be mobile and 
permits timely access to the electronic health record and 
reporting applications for maximum efficiency in the clinical 
practice. The handheld equipment can be transported into 
the mother’s room without the full cart for a less obtrusive 
experience for the family and to maximize bedside 
screening opportunities.
AABR and OAE screening equipment settings are consistent 
across all units. Of note, the equipment that was in use 
from 2015 to 2018 included the ALGO 5 Newborn Hearing 
Screener for AABR and Otodynamics Echoport 292 for 
transient otoacoustic emissions (TEOAE). The Otodynamics 
Otoport TE+DP OAE+AABR was in use from 2018 to 2019.
Data Management
Results and risk factors are entered into an internally 
created database called the Early Hearing Detection and 
Intervention (EHDI) application (developed at Mayo Clinic 
Rochester, 2009). This application was designed to track 
Table 1
Overview of Birth Cohort from the Newborn Nursery 




Year 2015 2016 2017 2018 2019
Birth Cohort 1899 1839 1903 1882 1921
Hearing 
Screenings
Pass 1850 1774 1800 1747 1803
Refer/
Fail 49 65 103 135 118
Note. Screening results of pass in both ears and the target 
for this investigation of referred in one or both ears also 
depicted for 2015 to 2019. The thick vertical line delineates 
baseline (2015–2017) prior to implementation of the 
congenital cytomegalovirus (cCMV) screening triggered by 
refer/fail on newborn hearing screening (active since 2018).
Figure 1
Overview of Two Step Protocol in the Newborn Hearing 
Screening Workflow
Note. The first level of screening (Step 1) uses otoacoustic 
emission (OAE) technology and the second step uses 
automated auditory brainstem response (AABR) technology. 
Refer/Fail outcomes prompt next level of screening.
 
Newborn Hearing Screening Protocol
Audiology staff, including audiology assistants and 
audiologists, conduct the newborn hearing screenings 
at Mayo Clinic Rochester. On the newborn nursery unit, 
screening is conducted using a two-step method (See 
Figure 1). Otoacoustic emissions (OAE) are used as a first 
level screening. Screening is considered complete if there 
is a passing result for both ears using OAE. Automated 
auditory brainstem response (AABR) is conducted if there 
is a refer result on the first OAE screening. Screening is 
considered complete if there is a passing result for both 
ears using the AABR technology. In the NICU settings, 
screening is conducted using only the AABR technology. 
Screening is considered complete if there is a passing 
result for both ears. A maximum of two screening attempts 
are conducted during the inpatient stay. For patients on all 
units, risk factors for early childhood hearing loss (JCIH, 
2007; 2019) are reviewed and documented.
Location
The focus of this evaluation is on the newborn nursery 
unit, where screening is conducted by one audiologist 
coordinator, seven audiology assistants, and two 
audiology doctoral student externs. The location of 
screening varies and is prioritized for family-centered 
care. Screening is initially offered to be conducted at the 
mother’s bedside and with parent(s) present whenever 
possible. This aspect of the program lends a family-
centered care emphasis and is the most common location 
for screening in our practice.
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Refer on newborn 
hearing screening in one 
or both ears
cCMV testing order 
activated 
(urine cCMV PCR; if not 






Prompts referral to 
Pediatric Infectious 
Disease Consultation
Prompts referral for 
Audiologic Evaluation and 
Monitoring
Test not obtained
Notify primary care to 
activate order 
(urine cCMV PCR; if no 
urine order saliva cCMV 
PCR)
inpatient and outpatient screening as well as follow up 
results for newborn hearing screening. The audiologist 
or audiology assistant creates a note in the electronic 
health record as well. Results are also sent electronically 
to the MDH. Data is exported from the handheld units to 
minimize errors due to manual entry. A program coordinator 
maintains the internal EHDI database, oversees review of 
risk factors for early childhood hearing loss, monitors follow 
up, and directs the ongoing quality improvement initiatives.
Patient Education
Newborn hearing screening results are delivered by 
the examining audiologist or audiology assistant to 
the parent(s) at the time of the screening. Results are 
delivered verbally and in writing as standard practice. In 
person, tablet, or telephone language interpreters are 
used when appropriate. Two patient education brochures 
are offered to families. The first brochure describes the 
screening process and explains why hearing screening 
is being done for a newborn. This brochure also has a 
checkbox for a pass or refer result so that the family has a 
record of the results before hospital dismissal. The family 
also has access to the screening results in the electronic 
health record patient portal. The second brochure has a 
list of typical developmental milestones for speech and 
language abilities up to age 5 years and is intended as a 
reference for parents to use while monitoring their child’s 
speech and language development.
When a baby is leaving the hospital with a refer result, the 
person who conducts the hearing screening documents this 
in the internally created EHDI database and in the note in the 
Figure 2
Overview of cCMV Testing Workflow for Newborns Triggered by Refer/Fail On Newborn Hearing Screening by 21 Days of Life
Note. Congenital cytomegalovirus(cCMV) testing ordered and sample collected prior to hospital dismissal. PCR = 
polymerase chain reaction. 
electronic health record and sends a message (also through 
the electronic health record) to the audiology scheduling 
team. The scheduling team contacts the family directly to 
schedule an outpatient rescreen appointment in 1 to 2 weeks.
Congenital Cytomegalovirus (cCMV) Testing Protocol
For this evaluation, patients leaving the hospital with a 
refer result on newborn hearing screening in one or both 
ears were offered cCMV testing. This included patients 
with a refer after one attempt if a second attempt is not 
possible before discharge. cCMV testing was performed 
as urine PCR (polymerase chain reaction) or saliva swab 
depending on what was feasible at the time of collection 
prior to hospital dismissal (e.g., Rawlinson et al., 2017; 
JCIH, 2019). Refer to Figure 2 for workflow of cCMV 
testing prompted by hearing screening outcome. This was 
implemented in January 2018 and this article reviews the 
outcomes over a two-year period (2018 to the end of 2019).
In addition to the previously described process for newborn 
hearing screening above, the person who conducts the 
hearing screening also notifies the nurse caring for the 
patient that the patient will be leaving with a refer result 
(one ear or two) for hearing screening. This prompts the 
nurse to activate the cCMV collection order set in the 
electronic health record (and workflow in Figure 2). The 
nurse informs the family that cCMV testing is completed 
whenever a patient is leaving the hospital with a refer 
result on newborn hearing screening. The nurse collects 
a sample for this test (as appropriate). Urine is the 
preferred specimen, but saliva (buccal swab) is considered 
appropriate if urine cannot be collected in a timely manner.
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PCR testing is completed at the Mayo Clinic Laboratories 
with results reported in the electronic health record in 1 
to 2 days. A PCR positive result triggers an immediate 
referral to the Pediatric Infectious Diseases Outpatient 
Clinic or a Pediatric Infectious Diseases inpatient 
consultation if the patient remains in the hospital. The 
Pediatric Infectious Disease provider then initiates an 
evaluation for other evidence of all organ involvement 
while awaiting final audiology results. If the evaluation 
indicates the infant has symptomatic cCMV, treatment is 
discussed with the parents or guardian.
Patient Education Development
cCMV testing results are delivered to the parent(s) by the 
managing primary care team. In a coordinated effort by the 
interprofessional care team, a patient education piece was 
created to assist the primary care providers in educating 
their patients and their families about cCMV and its 
connection to hearing loss. The piece, entitled “Congenital 
Cytomegalovirus (cCMV),” is a 12-page brochure created 
by Mayo Clinic Health Education and Content Services led 
by Audiology in collaboration with colleagues in Pediatric 
Infectious Disease, Genetics, Pediatric Otolaryngology, 
and Primary Care. Topics include a description of cCMV 
and causes, the relationship between cCMV and hearing 
loss, an overview of testing for cCMV, as well as treatment 
and prevention of cCMV.
Results
Interprofessional Collaborative Care Team Approach
An interprofessional collaborative care team was 
established to address this clinical practice need with 
the goal of initiating cCMV testing prior to dismissal 
from the hospital on all babies in the newborn nursery 
with a refer result on their newborn hearing screening. 
Interprofessional collaborative practice occurs when 
multiple health workers from different professions provide 
comprehensive services by working with patients, 
caregivers, and communities to deliver the highest quality 
of care across settings (WHO, 2010). The Interprofessional 
Education Collaborative (IPEC, 2016) further defined 
several competencies for teams of professionals working 
toward this type of practice. These include a climate 
of mutual respect and shared values, clearly defined 
roles and responsibilities, responsive and responsible 
communications with patients and their families as well 
as other professionals, and application of the principles of 
effective team dynamics.
For the purposes of this project, the interprofessional 
collaborative care team (See Figure 3) included 
representatives from the following specialty areas: 
Audiology, Genetics, Pediatric Infectious Disease, 
Pediatric Otolaryngology, Nursing, Primary Care (Family 
Medicine; Community Pediatrics), Neonatology, Hospital 
Desk Operations, Patient Appointment Services, and 
Patient Education. Representatives from the various 
groups worked together in smaller groups to accomplish 
portions of the project. For instance, pediatric expert 
representatives from audiology, infectious disease, 
genetics, pediatrics, and otolaryngology collaborated to 
create a patient education piece (described in Patient 
Education Development) designed to support primary care 
providers when discussing the concept of cCMV testing 
with parents.
Defined Care Team Pathway for Audiology (Outpatient)
To facilitate the goal that all babies who do not pass 
hearing screening will undergo cCMV testing by 21 days of 
age, care pathways within the inpatient setting (see Figure 
2 above) as well as in the outpatient setting (Figure 4) 
were defined as part of this project. Our objective was to 
develop a follow up plan for all babies who test positive for 
cCMV, keeping in mind that some may be found to have 
normal hearing. Figure 4 provides an overview of the care 
team coordination and plan for additional monitoring and 
management.
With implementation of a cCMV testing program into the 
clinical practice, an audiological monitoring pathway and 
protocol needed to be defined to account for individuals 
testing positive for cCMV and based on hearing status. 
The testing within this protocol will vary slightly depending 
on the patient population and individualized patient needs. 
Primary populations following this protocol will be patients 
who test positive for cCMV and who (a) Refer, miss, or 
refuse on newborn hearing screening and subsequently 
have confirmed sensorineural hearing loss, conductive 
hearing loss, or mixed hearing loss; and (b) Refer, miss, 
or refuse on newborn hearing screening and subsequently 
have confirmed hearing sensitivity within normal limits.
An interprofessional collaborative care team-based 
approach is critical when serving patients with cCMV with 
or without hearing loss. Clearly defined clinical pathways 
for the identification and management of cCMV can 
facilitate early intervention options. The care team needed 
for an effective monitoring program is one in which team 
Figure 3
Overview of Interprofessional Collaborative Care Team 
Approach
Note. There are many other collaborating providers; 
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members from different professions work in collaboration 
for timely identification, monitoring, and intervention as 
appropriate. Four of the professions (see Figure 3) are 
described in detail below for an overview of this approach.
Audiology
For Audiology, when babies refer on inpatient newborn 
hearing screening (refer to Figure 1), patients are 
immediately scheduled for outpatient rescreen within 1 to 2 
weeks. If there is a refer result on the outpatient rescreen 
of hearing, then patients proceed with a scheduled 
diagnostic audiologic evaluation with an audiologist as 
soon as possible (typically, within 1–2 weeks). Audiologic 
evaluation may include frequency-specific threshold 
auditory brainstem response (ABR), auditory steady state 
response (ASSR), otoacoustic emissions (may include 
TEOAEs and distortion product otoacoustic emissions 
[DPOAEs]), and immittance measurements (including 
tympanometry and acoustic reflex testing). Evaluation and 
confirmation of hearing status may occur over multiple 
visits.
When audiologic evaluation leads to diagnosis of hearing 
loss, the next steps (refer to Figure 4; AUD section) are 
to monitor every 3 months until age 1, every 6 months 
until age 3, and annually until age 19. When audiologic 
evaluation leads to diagnosis of hearing sensitivity within 
normal limits, the next steps are to monitor every 3 months 
until age 1, every 6 months until age 3, and annually until 
age 19. Although the timing of the monitoring visits is 
the same for the two populations, the specific monitoring 
tools are different. The testing for the population with a 
diagnosis of hearing sensitivity within normal limits will 
focus on and prioritize objective screenings, such as OAE 
and tympanometry unless change in hearing is more highly 
suspect (modified from Figure 2 in Foulon et al., 2015).
Figure 4
Care Team Coordination and Management Plan for Individuals Testing Positive for cCMV
Note. Care team coordination and management plan defined prospectively to define care pathway for individuals testing 
positive for congenital cytomegalovirus (cCMV) with specific focus on differences between care plan for individuals with 
hearing loss versus those with typical hearing. Please note this is an overview rather than exhaustive care plan in which 
individualized patient needs are also addressed. ABR = auditory brainstem response; OAE = otoacoustic emissions.
*If initiated, valganciclovir treatment is for 6 months unless adverse effects prevent the full course of treatment.
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Pediatric Otolaryngology
For Pediatric Otolaryngology, there is a close partnership 
with Audiology when audiologic evaluation leads to 
diagnosis of hearing loss (refer to Figure 4; ORL section). 
Additional medical evaluation of hearing loss may include 
detailed review of medical history, brain imaging for 
medical evaluation to help predict neurodevelopmental 
outcomes, referrals for speech and language development 
evaluation, et cetera. Efforts are led by otolaryngology for 
medical management of conductive hearing loss, which 
may include partnership with primary care teams. Pediatric 
Otolaryngology will often serve as the lead for early 
medical clearance for amplification or rehabilitation trials 
as well as the entry point for referrals for consideration 
of early cochlear implantation as appropriate. Specific 
to cCMV positive cases, additional management may 
include brain imaging for medical evaluation to help predict 
neurodevelopmental outcomes, early medical clearance for 
amplification and (re)habilitation trials, and consideration of 
early cochlear implantation as appropriate.
Genetics
For genetics, the identification of cCMV positive individuals 
in combination with hearing status helps guide next steps 
for the care plan (refer to Figure 4; CGE section). Additional 
work-up may include: utilization of evaluations obtained 
from care team, referral to pediatric ophthalmology (and 
other specialties as needed), and detailed family history 
and genetic counseling as appropriate. Targeted genetic 
testing is warranted, particularly, if there is a family history 
of hearing loss suggesting that there may be coincident 
cCMV as well as a genetic condition. Negative targeted 
genetic testing in the face of positive cCMV testing 
provides supporting evidence that cCMV alone would be 
the underlying cause of hearing loss.
Pediatric Infectious Disease
For Pediatric Infectious Disease, evaluation for evidence of 
symptomatic cCMV disease and treatment for symptomatic 
infants are the key considerations and components 
to manage (refer to Figure 4; IFD section). Next steps 
following a cCMV positive test result include physical 
examination; lab studies such as Complete Blood Count 
(CBC) with differential, liver function tests (LFT), creatinine; 
and brain imaging (preferably MRI). Developmental 
evaluation should begin at the first year for children with 
symptomatic cCMV on a case by case basis. Practitioners 
will also want to review audiology in at least 6 month 
intervals through age 3 years and align them with the 
prospective monitoring (defined in Figure 4; AUD section).
Treatment of symptomatic cCMV disease is led by Pediatric 
Infectious Disease in partnership with the broader care 
team. Specific to cCMV treatment, infants are examined 
at least monthly with dose adjustments of valganciclovir 
based on weight gain and monitoring for adverse effects of 
oral valganciclovir treatment including CBC with differential, 
liver function tests, and creatinine. Monitoring of hearing 
helps support the treatment which may be conducted 
through age 19 years based on need (as described above).
Hearing-Targeted cCMV Testing
Table 2 provides an overview of the numbers of newborns 
who did not pass hearing screening in both ears and cCMV 
testing. cCMV testing was implemented in January 2018 and 
here we review outcomes over a two-year period (2018 to 
the end of 2019) with baseline data reviewed from January 
2015 to December 2017. During this time, 1882 newborns 
were screened in 2018 and 1920 screened in 2019 (refer to 
Table 1). The referral rate from newborn hearing screening 
is displayed by year in Table 2 with the 5-year average of 
5% of newborns screened referred for hearing. Of those 
Table 2




Year 2015 2016 2017 2018 2019
Hearing 
Screenings
Refer Rate (refer total/ birth 
cohort in %) 2.58% 3.53% 5.41% 7.17% 6.14%
Refer/Fail 49 65 103 135 118
cCMV 
Testing
Hypothesized   
Test Positive 1 2 3 4 3
Actual   
Test Complete    112 115
Test Positive    0 1
Test Negative    112 114
Note. Screening results of pass in both ears and the target for this investigation of referred in one or both ears also 
depicted for 2015 to 2019. The thick vertical line delineates baseline (2015–2017) prior to implementation of the congenital 
cytomegalovirus (cCMV) testing triggered by refer/fail on newborn hearing screening (active since 2018). The gray shading 
denotes hypothesized values or intentionally blank cells prior to the initiation of cCMV testing.
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that refer on hearing screening, we anticipated to find about 
2 to 3 babies per year from our birth cohort that would 
refer for our monitoring protocol based on our program 
data from 2015 to 2017 (see Table 2). This referral rate for 
cCMV was predicted based on prior evaluations at similar 
institutions (2.7% refer rate; Choi et al., 2009). Based on 
these predictions, we planned a monitoring protocol that we 
expected would be manageable within the framework of our 
existing clinical practice (see Figure 2).
Most of those individuals that referred on newborn 
hearing screening were tested for cCMV (83.0% in 2018 
and 97.5% in 2019). No newborns were identified via 
targeted testing for cCMV in 2018 and only one patient 
was identified in 2019. This is less than our hypothesized 
cCMV refer rate of 4 in 2018 and 3 in 2019 (Table 2).
Discussion
Congenital cytomegalovirus (cCMV) is a cause of 
neurodevelopmental delay in children and a common 
cause of nonhereditary sensorineural hearing loss (CDC, 
2020; Goderis et al., 2014; Kenneson & Cannon, 2007; 
Kimberlin et al., 2015). Although prevalent, cCMV has 
gone largely undetected because most babies that are 
cCMV positive are asymptomatic. The early detection of 
hearing loss may help identify cCMV as well as promote 
early intervention for hearing loss. In our practice, 
exploration of hearing-targeted screening for cCMV was an 
initial step in advancing toward the goal of universal cCMV 
testing for all newborns and for promoting earlier detection 
of delayed onset or progressive hearing loss. In this article, 
we described our efforts focused on defining the care 
pathway for the identification and audiologic monitoring of 
individuals who refer on newborn hearing screening and 
subsequently test positive for cCMV by 21 days of age 
in the newborn nursery population. Three primary study 
objectives were to (a) define the interprofessional, team-
based approach to facilitate care pathways; (b) develop 
the clinical workflow for all babies who refer on inpatient 
hearing screening to get cCMV testing by 21 days of age; 
and (c) develop a hearing monitoring plan for all babies 
who test positive for cCMV.
Family-Centered Interprofessional Collaborative Care
The first objective was to establish an interprofessional 
collaborative care team (Figure 3) to address the 
immediate clinical practice need with the goal of initiating 
cCMV testing prior to dismissal from the hospital on 
all babies with a refer (in one or both ears) on their 
newborn hearing screening. As described above, many 
considerations and care team components were explored. 
Future considerations around defining pathways for 
inpatient versus outpatient screening and monitoring, 
internal versus external patient entry options, as well 
as hearing loss risk (based on degree and progression 
concern) will be explored. Moreover, longer term 
monitoring aspects warrant continued exploration given the 
small population and need for longer-term data (beyond 
the age of 19 years as described above).
Throughout the work on this project, the interprofessional 
care team also recognized that the child and their 
family are arguably the most important members of the 
overall team caring for the child. Family-centered care 
has always been a focus of the Mayo Clinic newborn 
hearing screening program. From the decision to offer 
to screen in the mother’s room as well as with parent(s) 
present to the scheduling of outpatient appointments 
before dismissal whenever possible, every decision 
is made with the experience of each family in mind. 
Family-centered care means working toward a respectful 
partnership between the family and the professionals. It 
also focuses on the principles of honoring and respecting 
the strengths, cultures, and expertise that families and 
professionals each bring to the health care interaction 
(Family Voices, 2021; Kuo et al., 2012; American Academy 
of Pediatrics, 2012). The principles of family-centered care 
were considered during all of the work on this project. 
It is well documented in the literature that parent and 
medical professional knowledge about cCMV is quite 
limited. Others are working on increasing awareness of 
cCMV among pregnant women, those who may become 
pregnant, and medical professionals (see resources in the 
National CMV Foundation, 2021; Park et al., 2020). During 
our project, the creation of the patient education brochure 
was part of our team’s efforts to increase awareness 
among providers and parents. One way the team could 
enhance these efforts in the future is to incorporate patient 
experience feedback and refinement of the materials.
Linking Newborn Hearing Screening and cCMV Testing
Development of a care pathway for a targeted approach 
to cCMV screening was the primary focus and one of 
the key objectives of this collaboration. Based on review 
of available literature, we anticipated that the newborn 
hearing screening program would identify more individuals 
with cCMV using this targeted approach to testing based 
on hearing screening outcomes. Specifically, we predicted 
a referral rate by year based on prior evaluation at a similar 
institution (e.g., Choi et al., 2009) which estimated about 
2.7%. Our predicted estimates for the newborn nursery 
population is displayed by year in Table 2. As can be seen 
from two years of this targeted approach, we anticipated 
identification of approximately seven patients with cCMV. 
Instead, we identified only one newborn during the two 
years with the targeted screening (equating to a referral 
rate of 0.85% in 2019 and 0% in 2018). Outcomes from 
this study demonstrate the feasibility of a hearing-targeted 
cCMV testing paradigm in our clinic and establishes the 
framework for expanded neonatal cCMV screening or 
universal screening for cCMV in the future. This aligns with 
prior published efforts (Diener et al., 2017; Fowler et al., 
2017; Haller et al., 2020; Krishna et al., 2020).
It is expected that more cCMV positive cases would be 
identified if a universal approach to cCMV testing were 
implemented. Because hearing loss that is secondary 
to cCMV is often progressive or later-onset in nature, a 
universal approach to cCMV testing and monitoring would 
help to identify those patients who receive a pass result on 
their newborn hearing screening and should be monitored 
for hearing changes (e.g., Haller et al., 2020). A universal 
cCMV testing approach would further the critical goals 
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of timely detection and hearing loss prevention, while 
promoting accessibility and affordability of care (e.g., Choi 
et al., 2009).
Audiologic Monitoring of Patients with cCMV Positive 
Outcomes
Before cCMV testing was implemented (see Figure 2), 
the audiologists worked to define a protocol for monitoring 
the newborns who test positive for cCMV. The defined 
protocol (see Figure 4), described earlier is similar in 
approach for those who have a higher degree of suspicion 
for or are known to have hearing loss as it is for those 
who continue to have results suggesting hearing that is 
within normal limits. The main difference is a focus on 
streamlined screening using more objective measures for 
those who continue to exhibit typical hearing in the context 
of a larger diagnostic assessment and monitoring plan as 
appropriate (e.g., Foulon et al., 2015; Park et al., 2014). 
There are ongoing multi-site studies from leading research 
centers in this realm (e.g., Choi et al., 2009; 2013; Haller 
et al., 2020; Park et al., 2014) validating various types of 
testing for cCMV and looking at the efficacy of treatment 
on hearing loss prevention. Findings from these continued 
efforts will be key for informing future changes in clinical 
practices and prioritizing global efforts for early detection 
and monitoring of hearing loss across the life span (e.g., 
JCIH, 2019; WHO, 2021).
Lessons Learned and Future Considerations
There are several aspects to consider when testing for 
cCMV, from the perspectives of the patient and their family 
as well as the interprofessional care teams in relation to 
hearing monitoring. Several of these considerations were 
gathered as part of the development of this clinical practice 
initiative and represent several areas needing further and 
larger scale exploration. Here we highlight considerations 
for social, clinical practice, and longer-term/life-span care 
approach.
Social considerations may include such items as the 
patient’s birth hospital may not be their managing 
hospital, requiring internal and external care pathways 
to be clearly defined. Patient and family ability to return 
for frequent monitoring (e.g., travel/financial burden) 
may also be a factor to address for the clinical program. 
Patient education materials may be overwhelming or 
not specific to the needs of the individual. Moreover, 
variability may exist in expected outcomes based 
on elected treatment and management options. 
Affordability and accessibility of care also warrants future 
consideration.
Clinical practice considerations may include the fact that 
infectious disease treatment options for symptomatic 
cCMV symptoms require close monitoring and may 
have varied outcomes. The individualized treatment 
approach supported through the interprofessional 
collaborative care team is deemed to be important for 
this and warrants future investigation. The complexity of 
audiologic evaluation in young children as well as in those 
who are neurologically complex is also a consideration 
given screening tool limitations and balancing affordability 
of preventative monitoring. There may be limitations 
to appointment availability and coordinating between 
audiology and associated sub-specialties (e.g., Pediatric 
Infectious Disease, Genetics, Pediatric Otolaryngology, 
etc.). The timeline for cCMV testing and confirming hearing 
status is short to maximize treatment and management 
options. Until cCMV testing is universal, allowing 
early intervention for sensorineural hearing loss and 
developmental delay where appropriate (Rawlinson et al., 
2017), current workflows require ordering of the test and 
this can increase the risk of missed tests.
Considerations across the lifespan and long-term for 
meeting the needs of the patient are worth immediate 
consideration as well as continued refinement as evidence 
emerges. Long term audiologic monitoring is recommended 
for those identified with cCMV regardless of newborn 
hearing screening outcome given potential risk for later 
onset hearing loss. The details of how often and what 
tools are rapidly emerging with increasing exploration as 
balancing accessibility, affordability, and quality of care 
continues to be weighed. It is our recommendation that 
clinical care pathways should be tailored to the individual 
needs of the patient and based on treatment options elected.
Conclusion
Although cCMV is the leading non-genetic cause of 
childhood hearing loss in the United States, there are 
not widespread established practices for cCMV testing 
universally at birth or on babies who refer on newborn 
hearing screening. Development of this interprofessional 
quality improvement project has greatly enhanced 
Mayo Clinic protocols and care plans for working 
with patients with cCMV and their families. It has also 
enhanced our ability to make recommendations for 
patients later identified with CMV. It has strengthened 
the interprofessional collaborative care relationships that 
audiology has with primary care and various specialties. 
Although this targeted screening project has identified 
fewer patients testing positive for cCMV than anticipated, 
it could be expected that the implementation of a program 
such as this could have positive implications for practices 
that have the resources to manage necessary referrals 
and follow up. Moreover, until cCMV testing is universal, 
clinical protocols need to account for the complexities of 
individualized care in partnership with interprofessional 
care team coordination.
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